| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 |
| 05 Nov 2026 |
Form 4: Magrath George, Director
Sold 28,258 shares ($110K) |
| 03 Nov 2026 | 144 |
| 27 Oct 2026 | SCHEDULE 13G |
| 27 Oct 2026 |
Form 4: Schachle Joseph K, Chief Operating Officer
Sold 4,767 shares ($17K) |
| 27 Oct 2026 |
Form 4: Yerxa Benjamin R, Director
Sold 33,189 shares ($117K) |
| 27 Oct 2026 |
Form 4: Gagnon Robert E., Chief Financial Officer
Sold 14,000 shares ($49.6K) |
| 27 Oct 2026 |
Form 4: Magrath George, Director
Sold 9,591 shares ($34.4K) |
| 23 Oct 2026 | 144 |
| 23 Oct 2026 | 144 |
| 23 Oct 2026 | 144 |
| 21 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease George Magrath, MD Retina in Rio 2026 |
| 02 Oct 2026 |
Form 4: Foundation Fighting Blindness Retinal Degeneration Fund, Director and 1 other
Sold 556,000 shares ($2.76M) |
| 11 Sep 2026 |
Form 4: Magrath George, Director
Received 392,157 shares by exercise or conversion ($451K) · Gave up 75,541 shares to cover exercise price or tax ($451K) |
| 11 Sep 2026 |
8-K: Regulation FD Disclosure
OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 |
Loading...